tiprankstipranks
Blurbs

Arcturus Therapeutics (ARCT) Receives a Hold from Robert W. Baird

Robert W. Baird analyst Research Report) on August 9 and set a price target of $18.00. The company’s shares closed yesterday at $17.48.

According to TipRanks, Beatty is a 4-star analyst with an average return of 5.7% and a 50.98% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Blueprint Medicines, and Leap Therapeutics.

Currently, the analyst consensus on Arcturus Therapeutics is a Hold with an average price target of $28.00, a 60.18% upside from current levels. In a report released yesterday, Citigroup also maintained a Hold rating on the stock with a $22.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Arcturus Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.24 million and a GAAP net loss of $51.17 million. In comparison, last year the company earned a revenue of $2.13 million and had a GAAP net loss of $56.35 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Read More on ARCT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More